Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
InFlectis BioScience logo — Harnessing expertise in cellular defense and drug discovery...

InFlectis BioScience

Harnessing expertise in cellular defense and drug discovery to develop molecules targeting misfolded protein disorders

Founded 2013 2-10 employees Grant Total: $9.34M Biopharma, Biotechnology +2

General Information

Company Name InFlectis BioScience
Founded Year 2013
Employees 2-10
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with InFlectis BioScience. To contact InFlectis BioScience, visit inflectis-bioscience.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does InFlectis BioScience compare?

A PDF of InFlectis BioScience and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting InFlectis BioScience soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About InFlectis BioScience

InFlectis BioScience is a biopharmaceutical startup dedicated to developing molecules targeting misfolded protein disorders. Leveraging their expertise in the cellular defense system and drug discovery, the company focuses on identifying and developing small molecules that modulate critical proteins involved in misfolded protein disorders. Founded in 2013, the company operates in the biopharma, biotechnology, healthcare, and pharmaceutical industries. The significance of Endoplasmic Reticulum (ER) proteostasis for cellular function and survival cannot be overstated. Disturbances in the ER's folding capacity can lead to the accumulation of unfolded or misfolded proteins, causing ER stress. In response to this, the mammalian ER employs a sophisticated machinery, known as the unfolded protein response (UPR), to maintain cellular integrity. In April 2024, InFlectis BioScience received a $649.60K grant investment from the National Multiple Sclerosis Society (NMSS), highlighting external validation and support for their groundbreaking work in combating misfolded protein disorders. With its innovative approach and strong industry presence, InFlectis BioScience exemplifies the potential for growth and impact in the biopharmaceutical sector.

Business keywords: Cellular defense, Drug discovery, Protein misfolding disorders, Endoplasmic Reticulum (ER) proteostasis, Unfolded protein response (UPR), Misfolded protein disorders, Orphan diseases, Charcot-Marie-Tooth (CMT), Amyotrophic Lateral Sclerosis (ALS), Neuromuscular diseases, Inflammatory diseases, Integrated Stress Response (ISR) modulators, Clinical Stage, Small molecules

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $649.60K 1
National Multiple Sclerosis Society (NMSS)
30 Apr 2024
Grant $943.00K 1
The ALS Association
03 Jan 2024
Series A €6.00M 4
Crédit Mutuel Innovation Go Capital Remiges Ventures
Crédit Mutuel Innovation, Go Capital +2
03 Jun 2016
Seed Round €1.75M 1
Go Capital
Go Capital
13 Jan 2015

InFlectis BioScience Alternatives & Competitors

View All Alternatives
InFlectis BioScience vs
aTyr Pharma
aTyr Pharma United States

aTyr is a biotherapeutics company engaged in the development of innovative medicines based on novel...

Post-IPO Equity
79 employees
Biotechnology, Health and Wellness
InFlectis BioScience vs
Kangpu Biopharmaceuticals, Ltd.
Kangpu Biopharmaceuticals, Ltd. China

Kangpu Biopharmaceuticals, Ltd. is a clinical-stage company focused on the discovery and development...

Series B
14 employees
Biopharma, Health Care
InFlectis BioScience vs
Cullgen Inc.
Cullgen Inc. United States

Powering protein degradation for tomorrow's medicines

Acquired
27 employees
Biotechnology, Pharmaceutical
View all alternatives

FAQ About InFlectis BioScience

Harnessing expertise in cellular defense and drug discovery to develop molecules targeting misfolded protein disorders
InFlectis BioScience was founded in 2013.
InFlectis BioScience operates in Biopharma, Biotechnology, Health Care and Pharmaceutical. Its work centres on Cellular defense, Drug discovery, Protein misfolding disorders and Endoplasmic Reticulum (ER) proteostasis.
InFlectis BioScience has approximately 2-10 employees.
InFlectis BioScience has completed 4 funding rounds, raising a total of $9.34M. The latest funding stage is Grant.
Top alternatives and competitors to InFlectis BioScience include aTyr Pharma, Kangpu Biopharmaceuticals, Ltd., Cullgen Inc., Evelo Biosciences, Actuate Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
InFlectis BioScience and aTyr Pharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for InFlectis BioScience, https://bouncewatch.com/company/inflectis-bioscience, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout